Stay updated on AK003 Study on KX2-391 Ointment 1% Clinical Trial
Sign up to get notified when there's something new on the AK003 Study on KX2-391 Ointment 1% Clinical Trial page.

Latest updates to the AK003 Study on KX2-391 Ointment 1% Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.3.2 was applied to the page, replacing the previous version v3.3.1. No visible updates to the study details or page layout.SummaryDifference0.0%

- Check25 days agoChange DetectedPublications section now notes that entries are automatically filled from PubMed and may not relate to the study, and the page revision is listed as v3.3.1.SummaryDifference0.1%

- Check32 days agoChange DetectedThe government funding notice banner was removed from the page; this does not affect the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check46 days agoChange DetectedNo substantive changes to the Study Details page; observed differences appear to be minor UI/formatting updates and do not alter eligibility criteria, outcomes, study design, or location lists. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check75 days agoChange DetectedAdded a government-operating-status notice and a new version tag; removed earlier drug-safety topic sections and the old revision tag.SummaryDifference3%

- Check76 days agoChange DetectedIntroduces version v3.1.0 and removes several risk-related topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs, and an older revision v3.0.2), implying a content scope reduction or reorganization with a new update tag.SummaryDifference0.3%

Stay in the know with updates to AK003 Study on KX2-391 Ointment 1% Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK003 Study on KX2-391 Ointment 1% Clinical Trial page.